Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0848771 (
neurological disability
)
928
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Human lymphoblastoid
interferon-alpha
was given by intraventricular administration via an Ommaya reservoir to a woman who entered Jabbour stage III at the age of 25 years. The first dose was of 150,000 IU, and daily doses were gradually increased; the total dose over a 42-day period was 33,550,000 IU. The patient's
neurological disability
index score before this treatment was 56.3%, and 75% after interferon treatment ended. After other treatment for 6 months, the patient died. Results of the autopsy showed perivascular lymphocyte infiltration in the cerebrum and brain stem, with diffuse gliosis and demyelination. The virus was isolated from the frontal lobes, also. The interferon treatment may have been a factor in this patient's deterioration.
...
PMID:Subacute sclerosing panencephalitis aggravated during the intraventricular interferon administration therapy. 767 23
Subacute sclerosing panencephalitis (SSPE) is a degenerative disease of the central nervous system that leads to death within a few years. Recently, it has been reported that combination therapy with intraparenchymal
interferon-alpha
(INF-alpha) and intraventricular ribavirin is effective. An 11-year-old SSPE patient whose clinical symptoms progressed rapidly, was treated first with intraventricular INF-alpha and then with combined intraventricular INF-alpha and ribavirin therapy. To monitor viral load over the course of the therapy, measles virus RNA was quantified using a real-time polymerase chain reaction assay. Measles virus RNA decreased rapidly after the INF-alpha therapy was started, paralleling the decrease in the measles antibody titer in the cerebrospinal fluid and the improvement in the
neurological disability
. After intraventricular ribavirin was combined with INF-alpha therapy, no further improvement was observed. The
neurological disability
gradually progressed, although the amount of virus RNA remained low.
...
PMID:Combination therapy with intraventricular interferon-alpha and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. 1285 May 18